Back

Effect of dapagliflozin on left ventricular mass in patients with kidney failure receiving maintenance hemodialysis: Primary results from the DAPA-HD trial

29 August 2026 (15:45 - 15:55)
Organised by: Logo
Congress Presentation Part of: Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Thomas A Zelniker

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
Nanoformulated omega-3-rich linseed oil reverses ex vivo the phenotype of monocytes of hemodialysis patients from a pro into an anti-inflammatory one with attenuated ROS formation and cell activation
Doctor G. Lima (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Analysis of the effect of specific therapy on exercise capacity in patients with anderson-fabry disease
Doctor A. Cuomo (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Omega-3 fatty acid supplementation and major cardiovascular events in maintenance haemodialysis: Systematic review and meta-analysis including PISCES
Doctor M. Egaimi (Ras al Khaimah, AE)
Abstract Slides Video
Presentation thumbnail
Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis
Doctor S. Rao (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 15:45 CET
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
31 August 2024
thumbnail
Congress Session
Advanced cardiorenal disease in clinical practice: implementation, interventions, and prognosis
31 August 2026
thumbnail
Congress Presentation
Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial
30 August 2026
thumbnail
Congress Presentation
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
28 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources